• Cytos Biotechnology Ltd., of Zurich, Switzerland, convened a bondholders' meeting on Nov. 10 to approve a proposed restructuring of outstanding convertible bonds, but failed to get sufficient votes to pass the proposal. Cytos said it will try to obtain further votes from bondholders who did not cast their votes.